Skip to main content

Table 4 Mean changes between baseline and 90 days for the attributes of survivors in the KyberSept trial: patients in hospital at 90 days and all-survivors

From: Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]

  In-hospital at day 90 All survivors*
Attribute Placebo (mean ± SD) AT III (mean ± SD) P Placebo (mean ± SD) AT III (mean ± SD)   P
Mobility (%) 33 ± 26 38 ± 28 >0.1 49 ± 24 51 ± 24 >0.1
Physical activity (%) 33 ± 27 39 ± 26 >0.1 48 ± 23 50 ± 23 >0.1
Communication/speech (%) 42 ± 42 61 ± 35 0.01 52 ± 34 57 ± 32 0.03
Level of alertness (%) 41 ± 39 59 ± 33 0.02 51 ± 32 56 ± 31 0.02
Energy level (%) 34 ± 27 43 ± 26 0.09 47 ± 23 51 ± 22 0.02
Overall QoL (%) 35 ± 28 44 ± 27 >0.1 51 ± 23 53 ± 23 >0.1
Karnofsky scale (%) 22 ± 19 31 ± 19 0.03 45 ± 19 47 ± 19 >0.1
  1. Scores range from 0 to 100, and changes may range from -100 to +100. Higher scores represent better quality of life (QoL) and increases (i.e. positive changes) represent improvement. *90-day values calculated by last observation carried forward analysis (see text). Nominal P value for two-sided, two-sample Wilcoxon test for differences between changes from baseline to 90-day QoL. AT, antithrombin.